
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For the Month of June, 2007

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_____.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: June 26, 2007

By: /s/ "Elizabeth Williams"

Elizabeth Williams
Director of Finance

EXHIBIT INDEX

99.1 Court File No. 07-CL-7015 *ONTARIO* SUPERIOR COURT OF JUSTICE COMMERCIAL LIST

**ONTARIO
SUPERIOR COURT OF JUSTICE
COMMERCIAL LIST**

THE HONOURABLE)
)
JUSTICE CAMPBELL)

THURSDAY, THE 21st
DAY OF JUNE, 2007



IN THE MATTER OF AN APPLICATION under section 192
of the *Canada Business Corporations Act*, being R.S.C. 1985, c. C-44;

AND AN APPLICATION under Rule 14.05(2) and Rule
14.05(3)(f) of the *Rules of Civil Procedure*;

AND IN THE MATTER OF a proposed plan of arrangement
involving Lorus Therapeutics Inc.

LORUS THERAPEUTICS INC. and 6650309 CANADA INC.

Applicants

APPLICATION UNDER the *Canada Business Corporations Act*, R.S.C. 1985, c. C-44, C. 192 and Rule 14.05 of the *Rules of Civil Procedure*.

ORDER

THIS MOTION, made by the Applicants, without notice, for an order amending the interim order dated May 16,2007 (the "Interim Order") was heard this day, at 330 University Avenue, Toronto.

ON READING the Notice of Motion and the Affidavit of Orysia Semotiuk, and on hearing the submissions of counsel for the Applicants:

1. **THIS COURT ORDERS** that paragraph 11 of the Interim Order is amended to read as follows:

"11. **THIS COURT ORDERS** that the vote required to pass the Arrangement Resolution shall be not less than (i) 66 2/3 per cent of the votes cast at the Securityholders' Meeting in person or by proxy by the Securityholders of record as of the Record Date; and (ii) a simple majority of the votes cast at the Securityholders' Meeting in person or by proxy by holders of common shares ("Shareholders") of record as of the Record Date other than High Tech Beteiligungen GmbH & Co. KG ("High Tech"), any related party of High Tech within the meaning of Rule 61-501 of the Ontario Securities Commission subject to the exceptions set out therein, and any person acting jointly or in concert with High Tech. The Securityholders shall vote as a single class, with each Shareholder being entitled to one vote for each common share held and, with each holder of options, warrants and convertible debentures being entitled to one vote for each common share such holder would have been entitled to receive upon the valid exercise or conversion of his, her or its options, warrants or convertible debenture, as applicable. Such vote shall be sufficient to authorize and direct Lorus to do all such acts and things as may be necessary and desirable to give effect to the Arrangement on a basis consistent with what is provided for in the Circular without the necessity of any further approval by the Securityholders, subject only to the final approval of the Arrangement by this Honourable Court."

2. **THIS COURT ORDERS** that paragraph 15 of the Interim Order is amended to read as follows:

"15. **THIS COURT ORDERS** that registered Shareholders who duly exercise their Arrangement Dissent Rights and who:


(a) are ultimately entitled to be paid fair value for their shares will be deemed to have their shares cancelled immediately prior to the effective date of the Arrangement (the "Effective Date") in consideration for the fair value paid to them by Lorus and will not be entitled to any other payment or consideration including any payment that would be payable under the Arrangement had such Dissenting Shareholders not exercised their Arrangement Dissent Rights; or

(b) are ultimately not entitled, for any reason, to be paid fair value for their shares,

will be deemed to have participated in the Arrangement on the same basis as a non-dissenting Shareholder in accordance with the Arrangement."

3. **THIS COURT ORDERS** that paragraph 17 of the Interim Order is amended to read as follows:

"17. **THIS COURT ORDERS** that notice to Shareholders of the right to dissent with respect to the Arrangement Resolution and to receive, subject to the provisions of this Interim Order, the fair value of Lorus' shares shall be good and sufficiently given by including information with respect thereto in the Circular to be sent to the Securityholders in accordance with paragraph 6 above."



ENTERED AT / INSCRIT À TORONTO
ON / BOOK NO:
LE / DANS LE REGISTRE NO.:

JUN 21 2007

PER/PAR: 

IN THE MATTER OF a proposed plan of arrangement involving Lorus Therapeutics
Inc.

LORUS THERAPEUTICS INC. et al.
Applicants

Court File No. 07-CL-7015

ONTARIO
SUPERIOR COURT OF JUSTICE
COMMERCIAL LIST
Proceeding Commenced at Toronto

ORDER

McCarthy Tetrault LLP
Box 48, Suite 4700
Toronto Dominion Bank Tower
Toronto, Ontario M5K 1E6

Geoff R. Hall LSUC# 347010
Tel. 416 601-7856
Fax: 416 868-0673

Solicitors for the Applicants

#4178118 v. 2